Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.50 |
| ▸ | HTR2C | P28335 | 13/20 | 0.50 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24628788 | 0.93 | MCOLN2 (0.46) | HTR2AHTR2CMCOLN2APOBEC3AAPOBEC3G | |
| SCHEMBL31720603 | 0.89 | MCOLN2 (0.49) | MCOLN2L3MBTL1ALDH1A1KMT2AHTR6 | |
| SCHEMBL31720602 | 0.88 | LMNA (0.49) | MCOLN2L3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL31720818 | 0.87 | LMNA (0.51) | MCOLN2ALDH1A1GAAKMT2AHTR6 | |
| SCHEMBL30936647 | 0.86 | MCOLN2 (0.44) | MCOLN2L3MBTL1ALDH1A1KMT2AHTR6 | |
| SCHEMBL30936702 | 0.85 | MCOLN2 (0.43) | HTR2CMCOLN2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL31720805 | 0.85 | MCOLN2 (0.43) | MCOLN2L3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL30936588 | 0.84 | MCOLN2 (0.43) | MCOLN2L3MBTL1ALDH1A1KMT2AHTR6 | |
| SCHEMBL29772916 | 0.84 | SCN8A (0.52) | HTR2AHTR2CMCOLN2ALDH1A1HTR6 | |
| SCHEMBL31720595 | 0.83 | MCOLN2 (0.42) | MCOLN2L3MBTL1ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340510-A1 | Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof | NINE SQUARE THERAPEUTICS CORPORATION (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4608389-A2 | SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | Nine Square Therapeutics Corporation (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024092235-A2 | SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | NINE SQUARE THERAPEUTICS CORPORATION (US) | 2024-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340510-A1 | Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof | TRPM2, TRPM6, TRPM5 | HTR2A 415/4885HTR2C 1474/4885MCOLN2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.